Promoter hypermethylation in white blood cell DNA and breast cancer risk

Journal of Cancer

Volumn 6, Issue 9, 2015, Pages 819-824

  Cho, Yoon Hee ^a,d   McCullough, Lauren E ^b   Gammon, Marilie D ^b   Wu, Hui Chen ^a   Zhang, Yu Jing ^a   Wang, Qiao ^a   Xu, Xinran ^c   Teitelbaum, Susan L ^c   Neugut, Alfred I ^a   Chen, Jia ^c   Santella, Regina M ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b IL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MONTANA   (United States)

Author keywords

BRCA1; Breast cancer; Promoter methylation; White blood cell DNA

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; DNA; RETINOIC ACID RECEPTOR BETA; TUMOR SUPPRESSOR PROTEIN; UVOMORULIN;

AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER TISSUE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREDICTIVE VALUE; PROMOTER REGION; TISSUE SECTION; TUMOR SUPPRESSOR GENE;

EID: 84947711558     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12174     Document Type: Article

References (35)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6): 415-28.
2. Lian ZQ, Wang Q, Li WP, Zhang AQ, Wu L. Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels. Int J Oncol. 2012; 41(2): 629-38.
3. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999;18: 1957-65.
4. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE et al. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000;60:4346-8.
5. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RAR{beta}2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002;62:2455-61.
6. Tserga A, Michalopoulos NV, Levidou G, Korkolopoulou P, Zografos G, Patsouris E, et al. Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep. 2012;27(5):1630-8.
7. Swift-Scanlan T, Vang R, Blackford A, Fackler MJ, Sukumar S. Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther. 2011; 11(10): 853-65.
8. Barekati Z, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, et al. Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer 2012; 12(1): 244.
9. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol. 2012; 19(9): 3107-15.
10. Müller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 2003; 63: 7641-5.
11. Müller HM, Ivarsson L, Schröcksnadel H, Fiegl H, Widschwendter A, Goebel G, et al. DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem. 2004; 50: 1065-8.
12. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 1999; 59: 3251-6.
13. Gammon MD, Neugut AI, Santella RM, Teitelbaum SL, Britton JA, Terry MB, et al. The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat. 2002; 74: 235-54.
14. Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, et al. Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1803-11.
15. Gammon MD, Santella RM, Neugut AI, Eng SM, Teitelbaum SL, Paykin A, et al. Environmental toxins and breast cancer on long island. I. polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev. 2002; 11(8): 677-85.
16. Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat. 2009; 115: 397-404.
17. Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, Gonzalez K, et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat. 2012; 131(1): 197-205.
18. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001; 61: 3410-8.
19. Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to Tamoxifen. Cancer Res. 2004; 64: 3807-13.
20. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 2004; 64: 4442-52.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
22. Kleinbaum DG, Klein M. Logistic regression; a self-learning text; 2nd ed. New York: Springer; 2002: p513.
23. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79(3): 340-9.
24. Fleiss JL. Statistical Methods for Rates and Proportions. Second edition. John Wiley & Sons, New York; 1981.
25. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila). 2011; 4(1): 23-33.
26. Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat. 2011; 129(1): 69-77.
27. Bosviel R, Garcia S, Lavediaux G, Michard E, Dravers M, Kwiatkowski F, et al. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol. 2012; 36(3): e177-182.
28. Wojdacz TK, Thestrup BB, Cold S, Overgaard J, Hansen LL. No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. Future Oncol. 2011; 7(12): 1451-5.
29. Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 2008; 10: R12.
30. Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, et al. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet. 2009; 18: 1332-42.
31. Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, et al. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res. 2012; 72(9): 2304-13.
32. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 2008; 3(7): e2656.
33. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000; 60(18): 5021-6.
34. Bu D, Lewis CM, Sarode V, Chen M, Ma X, Lazorwitz AM, et al., Identification of Breast cancer DNA methylation Markers optimized for fine-needle aspiration samples. Cancer Epidemiol Biomarkers Prev. 2013; 22(12): 2212-21.
35. Wojdacz TK, Thestrup BB, Overgaard J, Hansen LL. Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events. Diagn Pathol. 2011; 6: 116.